Brief: Nevro Corp - Latest Clinical Data on Nevro HFX Spinal Cord Stimulation Therapy Shows Substantial Improvement In Patients With Painful Diabetic Neuropathy
05/07/2022 12:40
July 5 (Reuters) - Nevro Corp NVRO.N :
* NEWLY RELEASED CLINICAL DATA DEMONSTRATES SUBSTANTIAL
IMPROVEMENT IN OVERALL HEALTH-RELATED QUALITY OF LIFE IN
PATIENTS WITH PAINFUL DIABETIC NEUROPATHY TREATED WITH NEVRO HFX
SPINAL CORD STIMULATION THERAPY
Source text for Eikon: ID:nPn8t1pgta
Further company coverage: NVRO.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nevro
See all newsNevro Corp reports results for the quarter ended December 31 - Earnings Summary
Nevro Corp expected to post a loss of 77 cents a share - Earnings Preview
Nevro Corp expected to post a loss of 77 cents a share - Earnings Preview
Nevro Corp expected to post a loss of 78 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Altus Power, Amazon, Nevro